Increasing demand for BSL-3 and ABSL-3 lab space in the wake of the COVID-19 pandemic is driving up interest in renovating existing research facilities to accommodate these high-containment spaces. Even a small BSL-3 lab can be a costly undertaking, with special attention required for security of both personnel and biohazards, location in the building, and waste disposal, as well as the design and commissioning of exhaust system.
Beacon Capital Partners and Trammell Crow Company are constructing Hyde Park Labs in Chicago. Designed by Elkus Manfredi Architects, Moody Nolan, and Interactive Design Architects (IDEA), the $225 million project involves the creation of a 13-story building atop an existing retail podium. The completed 370,000-sf facility will offer 300,000 rsf of Class A lab and office space spread over nine floors.
Kadans Science Partner is planning to construct a 139,000-sf research facility in Cambridge in the United Kingdom. Featuring a modular layout that can accommodate multiple tenants or a single entity, Merlin Place will provide best-in-class lab environments for the creation of new therapies, medical devices, and digital healthcare solutions. A flexible structural grid with adaptable floor heights will support a range of configurations, with vibration-mitigated suites available for sensitive instrumentation.
Regeneron Pharmaceuticals is planning to establish a biomedical research facility in Suffern, N.Y. The company recently invested $39 million to acquire the 235,000-sf Avon Innovation Center. Sited on 10 acres, the three-story structure originally housed chemistry labs and support spaces for the development of cosmetics, fragrances, and skincare products. HLW designed the facility, which was constructed between 2003 and 2005 by Skanska USA Building.
AstraZeneca is investing $300 million to establish a cell therapy manufacturing facility in Rockville, Md. Developed by Alexandria Real Estate Equites, the Class A+ property is located in the vibrant innovation ecosystem of the Alexandria Center for Life Science at Shady Grove. AstraZeneca has executed a 13-year lease for the entire 84,264-rsf building.
Alexandria Real Estate Equities opened a 215,000-sf life sciences center in early 2024 in San Francisco’s Mission Bay district. Designed by IwamotoScott Architecture in association with DGA and Powell Architecture, the seven-story building provides 133,000 sf of Class A lab space, 50,000 sf of office space, and 2,600 sf of ground-level retail.
Breakthrough Properties broke ground in February of 2024 on a 175,000-sf life sciences center in Cambridge in the United Kingdom. Designed by Henning Larsen and Feilden+Mawson, the five-story building will offer modern, flexible laboratories with integrated write-up areas. Vitrum by Breakthrough will also provide world-class offices, meeting rooms, collaboration spaces, and amenities. On the ground floor, a spacious lobby will open onto a landscaped square, complemented by outdoor terraces on the upper levels.
Imperial College London opened the £120 million Laboratory of Medical Sciences in January of 2024 on the Hammersmith Hospital Campus. Designed by Hawkins\Brown to support team science, this collaborative hub for translational research accommodates programs in genetics, sex-based disease differences, and heart and metabolic disorders. The 130,000-sf structure features highly controlled lab environments carefully interwoven with comfortable write-up spaces and shared amenities.
The Centre for Addiction and Mental Health (CAMH) began construction in January of 2024 on the Research & Discovery Centre in Toronto. Designed by TreanorHL and KPMB Architects, the 389,341-sf facility will catalyze the translation of medical breakthroughs into new solutions for patient care. This centralized home for CAMH’s research enterprise will feature open lab and office environments, space for clinical trials, and communal settings illuminated by natural light.
Global pharmaceutical firm XBiotech will break ground in early 2024 on an expansion of its Austin campus. Designed by MOD Architecture, the 46,000-sf R&D center will catalyze the discovery and development of innovative biomedical therapies, as well as accelerating the commercialization of the company’s Natrunix rheumatology treatment. Wet laboratories for infectious disease research will foster the creation of new vaccines and medications to address emerging health challenges.
AstraZeneca is partnering with Boston Properties to create a 570,000-sf R&D center in Cambridge’s Kendall Square. Housing approximately 1,850 employees, the 16-story building will offer world-class research environments for the creation of advanced biomedical therapies and vaccines. This nexus of innovation and discovery will feature flexible open laboratories arranged in neighborhoods with shared instrumentation suites and collaboration spaces.
The Vaccine and Infectious Disease Organization (VIDO), is becoming Canada’s Centre for Pandemic Research, preparing Canada for emerging health threats by expanding its expertise and infrastructure. This includes opening a new Vaccine Development Centre (VDC) to manufacture vaccines; constructing a new multispecies animal housing facility; enhancing its biosafety containment to the highest level to facilitate research on the most complex pathogens; and using its nearly five decades of success to attract top scientists.
The University of Virginia broke ground on the $350 million Paul and Diane Manning Institute for Biotechnology in December of 2023. Located in the Fontaine Research Park in Charlottesville, the 350,000-sf project will drive innovation in the fields of cellular therapy, gene therapy, nanotechnology, and drug delivery. By collocating state-of-the-art labs and core facilities with advanced manufacturing suites and clinical environments, the four-story building will accelerate the translation of medical discoveries into new solutions for patient care.
Aviva Investors began construction in December of 2023 on a three-story, 60,000-sf life sciences facility in Cambridge, U.K. Located in the Chesterford Research Park, the Sidney Sussex Building will provide 10 individual suites with fully fitted wet labs and open office areas that range from 2,226 sf to 8,409 sf. A dedicated floor of shared conference rooms will promote collaboration and exchange, complemented by inspiring outdoor settings for informal interaction.
Philadelphia-based Genesis AEC was able to reduce the square footage of a new translational medicine center of excellence by more than half and cut cost estimates by 16%, by reviewing the client’s needs versus wants; using innovative design practices, including a first-of-its-kind firewall design; and applying the approach known as “engineering, procurement, and construction management (EPCM).” The facility for a U.S.-based multi-national pharmaceutical company opened on Sept. 1, 2023.
